Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Trileptal subpoena

Executive Summary

Allegations of off label-promotion of Novartis' anti-epileptic Trileptal (oxcarbazepine) are under investigation by Philadelphia U.S. Attorney's Office, the company says July 14. The attorney's office issued a subpoena May 26 and is understood to have opened parallel civil and criminal investigations pursuant to privacy regulations under the Health Insurance Portability and Accountability Act. Boston Assistant U.S. Attorney Michael Loucks (now first assistant) has predicted that federal prosecutors are likely to bring lawsuits against drug companies that violate HIPAA's privacy provisions (1"The Pink Sheet" Nov. 3, 2003, p. 42)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046095

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel